Patents Assigned to CollaGenex Pharmaceuticals, Inc.
-
Patent number: 7232572Abstract: A method of treating rosacea in a human in need thereof comprising administering to said human a tetracycline compound in an amount that is effective to treat rosacea, but has substantially no antibiotic activity.Type: GrantFiled: February 18, 2005Date of Patent: June 19, 2007Assignee: CollaGenex Pharmaceuticals, Inc.Inventor: Robert A. Ashley
-
Patent number: 7211267Abstract: A method of treating acne in a human in need thereof comprising administering systemically to said human a tetracycline compound in an amount that is effective to treat acne but has substantially no antibiotic activity, without administering a bisphosphonate compound.Type: GrantFiled: April 5, 2002Date of Patent: May 1, 2007Assignee: CollaGenex Pharmaceuticals, Inc.Inventor: Robert A. Ashley
-
Patent number: 7014858Abstract: A method of treating telangiectasia in a human in need thereof comprising administering to said human a tetracycline compound in an amount that is effective to treat telangiectasia, but has substantially no antibiotic activity.Type: GrantFiled: October 15, 2002Date of Patent: March 21, 2006Assignee: CollaGenex Pharmaceuticals, Inc.Inventor: Robert A. Ashley
-
Patent number: 7008631Abstract: A method for simultaneously treating ocular rosacea and acne rosacea in a human in need thereof comprising administering systemically to said human a tetracycline compound in an amount that is effective to treat ocular rosacea and acne rosacea but has substantially no antibiotic activity.Type: GrantFiled: April 16, 2003Date of Patent: March 7, 2006Assignee: CollaGenex Pharmaceuticals, Inc.Inventor: Robert A. Ashley
-
Patent number: 6946453Abstract: The present invention provides new chemically modified 4-dedimethylaminotetracycline compounds that can be substituted with aryl, alkenyl, or alkynyl groups. The 7, 8, and/or 9 positions and methods for preparing such compounds. Other tetracycline compounds include the 4-dedimethylaminotetracycline derivatives with an oxime group, NH-Alkyl, or N—NH-Alkyl group substituted at the C4 position as well as C2 Mannich derivatives. The present invention also provides a method of treating a mammal suffering from conditions or diseases by administering to the mammal an effective amount of the new chemically modified tetracycline compounds.Type: GrantFiled: October 18, 2002Date of Patent: September 20, 2005Assignee: CollaGenex Pharmaceuticals, Inc.Inventors: Robert A. Ashley, Joseph J. Hlavaka
-
Publication number: 20040147492Abstract: A method of treating acne in a human in need thereof comprising administering systemically to said human a tetracycline compound in an amount that is effective to treat acne but has substantially no antibiotic activity, without administering a bisphosphonate compound.Type: ApplicationFiled: January 14, 2004Publication date: July 29, 2004Applicant: CollaGenex Pharmaceuticals, Inc.Inventor: Robert A. Ashley
-
Publication number: 20040002481Abstract: The present invention provides new chemically modified 4-dedimethylaminotetracycline compounds that can be substituted with aryl, alkenyl, or alkynyl groups. The 7, 8, and/or 9 positions and methods for preparing such compounds. Other tetracycline compounds include the 4-dedimethylaminotetracycline derivatives with an oxime group, NH-Alkyl, or N-NH-Alkyl group substituted at the C4 position as well as C2 Mannich derivatives. The present invention also provides a method of treating a mammal suffering from conditions or diseases by administering to the mammal an effective amount of the new chemically modified tetracycline compounds.Type: ApplicationFiled: June 10, 2003Publication date: January 1, 2004Applicant: CollaGenex Pharmaceuticals, Inc.Inventors: Robert Ashley, Joseph J. Hlavka
-
Patent number: 5827503Abstract: Oral hygiene is improved and diseases of the oral cavity are treated by oral application of a composition containing 0.02 to 0.25 weight percent alkyldimethylbenzylammonium chloride (BAC) and 0.05 to 2.0 weight percent sodium chloride dissolved in water, in the absence of other active ingredients. The BAC and sodium chloride act synergistically to allow the composition to sorb strongly to oral tissues and remain there for several hours.Type: GrantFiled: August 8, 1996Date of Patent: October 27, 1998Assignee: Collagenex Pharmaceuticals, Inc.Inventor: Christian Schwabe
-
Patent number: 5792446Abstract: A delivery system for controlled administration of a dentin-hypersensitivity-ameliorating composition to targeted areas is described. In particular, a bio-compatible delivery vehicle is described which contains unreacted, reactive materials dispersed therein. These materials form a dentin-hypersensitivity-ameliorating composition when reacted. Furthermore, these materials are separately encapsulated within protective encapsulating matrices to prevent the reaction thereof until delivery of the materials to a dentinal surface.Type: GrantFiled: February 18, 1997Date of Patent: August 11, 1998Assignee: Collagenex Pharmaceuticals, Inc.Inventor: Robert A. Ashley
-
Patent number: 5753711Abstract: In a method for preventing the spread of Helicobacter pylori from the oral cavity, the oral cavity is contacted with alkyldimethylammonium chloride. The contacting is advantageously used in conjunction with enteric antimicrobial therapy for H. pylori or for prophylaxis thereof.Type: GrantFiled: March 18, 1997Date of Patent: May 19, 1998Assignee: Collagenex Pharmaceuticals, Inc.Inventors: Christian Schwabe, Robert A. Ashley